The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Ruben A. Mesa

Division of Hematology and Medical Oncology

Mayo Clinic

Scottsdale

AZ 85259

USA

[email]@mayo.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA. 2009 - 2013
  • Department of Hematology, Mayo Clinic, Scottsdale, Arizona. 2003 - 2011
  • Mayo Clinic, Scottsdale, USA. 2009 - 2010
  • Mayo Clinic, 200 First Street, SW, Rochester, MN 55902, USA. 2007
  • Division of Hematology, Rochester, USA. 2007
  • Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, United States. 2006
  • Laboratory of Clinical Epidemiology, IRCCS Policlinico S. Matteo, Pavia, Italy. 2006
  • Division of Hematology and Internal Medicine, the Division of Hematopathology, and the Cancer Center Statistics Unit, Mayo Clinic, USA. 2002 - 2005

References

  1. The evolving treatment paradigm in myelofibrosis. Mesa, R.A. Leuk. Lymphoma (2013) [Pubmed]
  2. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. Emanuel, R.M., Dueck, A.C., Geyer, H.L., Kiladjian, J.J., Slot, S., Zweegman, S., Te Boekhorst, P.A., Commandeur, S., Schouten, H.C., Sackmann, F., Kerguelen Fuentes, A., Hernández-Maraver, D., Pahl, H.L., Griesshammer, M., Stegelmann, F., Doehner, K., Lehmann, T., Bonatz, K., Reiter, A., Boyer, F., Etienne, G., Ianotto, J.C., Ranta, D., Roy, L., Cahn, J.Y., Harrison, C.N., Radia, D., Muxi, P., Maldonado, N., Besses, C., Cervantes, F., Johansson, P.L., Barbui, T., Barosi, G., Vannucchi, A.M., Passamonti, F., Andreasson, B., Ferarri, M.L., Rambaldi, A., Samuelsson, J., Birgegard, G., Tefferi, A., Mesa, R.A. J. Clin. Oncol. (2012) [Pubmed]
  3. MPN blast phase: Clinical challenge and assessing response. Mesa, R.A., Tibes, R. Leuk. Res. (2012) [Pubmed]
  4. Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: Performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Mesa, R.A., Kantarjian, H., Tefferi, A., Dueck, A., Levy, R., Vaddi, K., Erickson-Viitanen, S., Thomas, D.A., Cortes, J., Borthakur, G., Pardanani, A.D., Estrov, Z., Verstovsek, S. Cancer (2011) [Pubmed]
  5. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Mesa, R.A., Yao, X., Cripe, L.D., Li, C.Y., Litzow, M., Paietta, E., Rowe, J.M., Tefferi, A., Tallman, M.S. Blood (2010) [Pubmed]
  6. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Mesa, R.A., Schwager, S., Radia, D., Cheville, A., Hussein, K., Niblack, J., Pardanani, A.D., Steensma, D.P., Litzow, M.R., Rivera, C.E., Camoriano, J., Verstovsek, S., Sloan, J., Harrison, C., Kantarjian, H., Tefferi, A. Leuk. Res. (2009) [Pubmed]
  7. How I treat symptomatic splenomegaly in patients with myelofibrosis. Mesa, R.A. Blood (2009) [Pubmed]
  8. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Mesa, R.A., Tefferi, A. Expert. Opin. Emerg. Drugs (2009) [Pubmed]
  9. New insights into the pathogenesis and treatment of chronic myeloproliferative disorders. Mesa, R.A. Curr. Opin. Hematol. (2008) [Pubmed]
  10. Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. Mesa, R.A. Hematology. Am. Soc. Hematol. Educ. Program (2007) [Pubmed]
  11. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Mesa, R.A., Niblack, J., Wadleigh, M., Verstovsek, S., Camoriano, J., Barnes, S., Tan, A.D., Atherton, P.J., Sloan, J.A., Tefferi, A. Cancer (2007) [Pubmed]
  12. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Mesa, R.A., Camoriano, J.K., Geyer, S.M., Wu, W., Kaufmann, S.H., Rivera, C.E., Erlichman, C., Wright, J., Pardanani, A., Lasho, T., Finke, C., Li, C.Y., Tefferi, A. Leukemia (2007) [Pubmed]
  13. Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia. Mesa, R.A., Quintás-Cardama, A., Verstovsek, S. Curr. Hematol. Malig. Rep (2007) [Pubmed]
  14. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Mesa, R.A., Nagorney, D.S., Schwager, S., Allred, J., Tefferi, A. Cancer (2006) [Pubmed]
  15. Tipifarnib: farnesyl transferase inhibition at a crossroads. Mesa, R.A. Expert. Rev. Anticancer. Ther (2006) [Pubmed]
  16. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Mesa, R.A., Powell, H., Lasho, T., Dewald, G., McClure, R., Tefferi, A. Leuk. Res. (2006) [Pubmed]
  17. Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options. Mesa, R.A., Barosi, G., Cervantes, F., Reilly, J.T., Tefferi, A. Best. Pract. Res. Clin. Haematol (2006) [Pubmed]
  18. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. Mesa, R.A., Tefferi, A., Lasho, T.S., Loegering, D., McClure, R.F., Powell, H.L., Dai, N.T., Steensma, D.P., Kaufmann, S.H. Leukemia (2006) [Pubmed]
  19. Practical management of classical myeloproliferative disorder patients: a clinician's guide. Mesa, R.A. Future. Oncology. (london,. England) (2006) [Pubmed]
  20. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Mesa, R.A., Li, C.Y., Ketterling, R.P., Schroeder, G.S., Knudson, R.A., Tefferi, A. Blood (2005) [Pubmed]
  21. Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia. Mesa, R.A., Tefferi, A. Semin. Oncol. (2005) [Pubmed]
  22. Pegylated interferon for the treatment of high-risk essential thrombocythemia. Mesa, R. Haematologica (2005) [Pubmed]
  23. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003. Mesa, R.A. Curr. Hematol. Rep. (2003) [Pubmed]
  24. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Mesa, R.A., Hanson, C.A., Li, C.Y., Yoon, S.Y., Rajkumar, S.V., Schroeder, G., Tefferi, A. Blood (2002) [Pubmed]
 
WikiGenes - Universities